Do analysts prefer ALVR or TVGN?

Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,312.43%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings and valuation, ALVR or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is ALVR or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Tevogen Bio N/A N/A -468.32%

Do analysts recommend ALVR or ANVS?

Annovis Bio has a consensus price target of $12.00, indicating a potential upside of 1,035.29%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, ALVR or ANVS?

Annovis Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is ALVR or ANVS more profitable?

AlloVir's return on equity of -71.03% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Annovis Bio N/A -685.98% -258.77%

Do analysts prefer CELU or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, CELU or ALVR?

Celularity has higher revenue and earnings than AlloVir. Celularity is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celularity $26.55M 1.63 -$91.72M -$2.73 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is CELU or ALVR more profitable?

AlloVir has a net margin of 0.00% compared to Celularity's net margin of -374.87%. Celularity's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -374.87% N/A -64.45% AlloVir N/A -71.03% -61.27%

Do analysts recommend EXOZ or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, EXOZ or ALVR?

eXoZymes has higher revenue and earnings than AlloVir. eXoZymes is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 531.43 -$9.16M -$1.19 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is EXOZ or ALVR more profitable?

AlloVir's return on equity of -71.03% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% AlloVir N/A -71.03% -61.27%

Do analysts rate ALVR or TIL?

Instil Bio has a consensus target price of $7.00, suggesting a potential upside of 14.19%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger valuation & earnings, ALVR or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Instil Bio N/A N/A -$71.37M -$4.47 N/A

Is ALVR or TIL more profitable?

Instil Bio's return on equity of -26.78% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Instil Bio N/A -26.78% -14.89%

AlloVir (ALVR) Competitors

$2.13 -0.10 (-4.48%)

As of 10/14/2026

Compare

ALVR vs. TVGN, ANVS, CELU, EXOZ, and TIL

Should you buy AlloVir stock or one of its competitors? AlloVir's main competitors and comparable companies include Tevogen Bio (TVGN), Annovis Bio (ANVS), Celularity (CELU), eXoZymes (EXOZ), and Instil Bio (TIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AlloVir compare to Tevogen Bio?

AlloVir (NASDAQ:ALVR) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Tevogen Bio's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Tevogen Bio	N/A	N/A	-468.32%

66.1% of AlloVir shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 65.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Tevogen Bio had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Tevogen Bio and 0 mentions for AlloVir. Tevogen Bio's average media sentiment score of 0.36 beat AlloVir's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Tevogen Bio	Neutral

Tevogen Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,312.43%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Tevogen Bio beats AlloVir on 8 of the 11 factors compared between the two stocks.

How does AlloVir compare to Annovis Bio?

AlloVir (NASDAQ:ALVR) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Annovis Bio has a consensus price target of $12.00, indicating a potential upside of 1,035.29%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

AlloVir's return on equity of -71.03% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Annovis Bio	N/A	-685.98%	-258.77%

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Annovis Bio	Neutral

Annovis Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 15.9% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Summary

Annovis Bio beats AlloVir on 6 of the 11 factors compared between the two stocks.

How does AlloVir compare to Celularity?

Celularity (NASDAQ:CELU) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

19.0% of Celularity shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Celularity has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Celularity had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Celularity and 0 mentions for AlloVir. Celularity's average media sentiment score of 1.39 beat AlloVir's score of 0.00 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Positive
AlloVir	Neutral

AlloVir has a net margin of 0.00% compared to Celularity's net margin of -374.87%. Celularity's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-374.87%	N/A	-64.45%
AlloVir	N/A	-71.03%	-61.27%

Celularity has higher revenue and earnings than AlloVir. Celularity is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.63	-$91.72M	-$2.73	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

Celularity beats AlloVir on 8 of the 13 factors compared between the two stocks.

How does AlloVir compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

eXoZymes has a beta of 3.19, indicating that its stock price is 219% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

66.1% of AlloVir shares are held by institutional investors. 58.0% of eXoZymes shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

eXoZymes has higher revenue and earnings than AlloVir. eXoZymes is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	531.43	-$9.16M	-$1.19	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, eXoZymes had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for AlloVir. eXoZymes' average media sentiment score of 1.18 beat AlloVir's score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Positive
AlloVir	Neutral

AlloVir's return on equity of -71.03% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
AlloVir	N/A	-71.03%	-61.27%

Summary

eXoZymes beats AlloVir on 8 of the 11 factors compared between the two stocks.

How does AlloVir compare to Instil Bio?

AlloVir (NASDAQ:ALVR) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Instil Bio's return on equity of -26.78% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Instil Bio	N/A	-26.78%	-14.89%

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Instil Bio has a consensus target price of $7.00, suggesting a potential upside of 14.19%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts clearly believe Instil Bio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Instil Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

66.1% of AlloVir shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Instil Bio had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Instil Bio and 0 mentions for AlloVir. Instil Bio's average media sentiment score of 1.79 beat AlloVir's score of 0.00 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Instil Bio	Very Positive

Summary

Instil Bio beats AlloVir on 10 of the 12 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.74M	$3.93B	$7.43B	$12.86B
Dividend Yield	N/A	3.66%	2.51%	19.61%
P/E Ratio	-0.11	12.63	274.94	25.22
Price / Sales	N/A	1,201.64	623.57	99.68
Price / Cash	N/A	118.95	76.19	51.56
Price / Book	0.07	16.07	10.40	5.96
Net Income	-$190.42M	-$22.69M	$3.50B	$380.92M
7 Day Performance	-14.80%	-6.92%	-3.89%	-3.33%
1 Month Performance	-33.44%	-12.35%	-7.10%	-5.34%
1 Year Performance	-56.80%	2.13%	1.70%	-4.58%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$2.13 -4.5%	N/A	-58.2%	$10.74M	N/A	N/A	110
TVGN Tevogen Bio	2.007 of 5 stars	$6.77 -4.7%	$100.00 +1,376.2%	-81.2%	$44.10M	N/A	N/A	18	News Coverage Analyst Forecast Gap Down
ANVS Annovis Bio	1.7613 of 5 stars	$1.02 -4.2%	$12.00 +1,082.3%	-41.8%	$43.32M	N/A	N/A	7
CELU Celularity	0.775 of 5 stars	$1.31 -8.1%	N/A	-38.7%	$42.38M	$26.55M	N/A	115	Short Interest Decrease
EXOZ eXoZymes	2.0547 of 5 stars	$4.60 +0.3%	N/A	-68.7%	$42.23M	$70K	N/A	32	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors